Opioid-Free Pain Protocol After Shoulder Arthroplasty

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomized, single blinded, clinical trial aims to investigate the efficacy of a multimodal pain control regimen for shoulder arthroplasty. Patients who receive a multimodal pain control regimen alone (study group) will be compared to patients who receive a multimodal pain control regimen plus a standard prescription of an opioid containing medication (comparison group). The primary outcome is average daily Numerical Rating Scale (NRS) pain score in the first 10 days after surgery. We hypothesize that there will be no significant difference in the primary outcome between the two groups.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Henry Ford Health System
• Treatments: Acetaminophen; Celecoxib; Dexamethasone; Epinephrine; Ibuprofen; Ketorolac; Oxycodone; Pregabalin; Tizanidine; Tramadol

Criteria

Inclusion Criteria:

• Consented and scheduled for primary anatomic or reverse total shoulder arthroplasty at a Henry Ford hospital location

Exclusion Criteria:

• Unable to receive or reply to mobile phone text messages.

• Unable to read or speak English

• Medical history of known allergies or intolerance to any of the medications prescribed as a part of this study (ie, Percocet, Ibuprofen, Pregabalin, Dexamethasone, Acetaminophen, Tizanidine, Magnesium, Celecoxib, Tramadol, Ropivacaine, Epinephrine, Ketorolac)

• Substantial alcohol or drug abuse

• Recent or current pregnancy

• History of narcotic use within 3 months prior to surgery

• Renal or hepatic impairment or dysfunction

• Use of blood thinner medication

• Peptic ulcer disease

• Gastrointestinal bleeding

• History of gastric bypass surgery